uniQure N.V. Sample Contracts

uniQure N.V. – uniQure N.V. Share Option Agreement Granted Under 2014 Share Incentive Plan, Amended and Restated effective as of June 13, 2018 (July 29th, 2019)
uniQure N.V. – Contract (July 29th, 2019)

WHEREAS, due to a scrivener’s error, the parties desire to revise Section 3.A and Section 3.B (Base Rent) of the First Amendment,  on the terms and conditions hereinafter set forth;

uniQure N.V. – Annual Report 2018 uniQure N.V. (May 6th, 2019)
uniQure N.V. – EMPLOYMENT AGREEMENT (February 28th, 2019)

THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of August 20, 2018 (the “Effective Date”), by and between uniQure, Inc., 113 Hartwell Avenue, Lexington, MA 02421 (the “Company”) and Dr. Robert Gut (the “Executive”), __________.

uniQure N.V. – AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (December 10th, 2018)

This AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”), is dated as of December 6, 2018 and is entered into by and among (a) (i) UNIQURE BIOPHARMA B.V., a private limited liability company incorporated and existing under the laws of the Netherlands, having its corporate seat at Amsterdam, the Netherlands and registered at the trade register of the Chamber of Commerce for Amsterdam under number 34275365 (“uniQure”), (ii) UNIQURE, INC., a Delaware corporation (“uniQure US”) (uniQure and uniQure US are hereinafter collectively referred to as “Borrower”), (iii) UNIQURE IP B.V., a private limited liability company incorporated and existing under the laws of the Netherlands, having its corporate seat at Amsterdam, the Netherlands and registered at the trade register of the Chamber of Commerce for Amsterdam under number 34275369 (“uniQure IP”), and (iv) UNIQURE N.V. (formerly uniQure B.V.), a public limited company incorporated and existing under th

uniQure N.V. – Contract (November 15th, 2018)

Approximately 53,343 rentable square feet of space in the Building, as more particularly shown as hatched, highlighted or outlined on the plan attached to the Lease as Exhibit lA

uniQure N.V. – UNIQURE N.V. and as Trustee (June 14th, 2018)
uniQure N.V. – UNIQURE N.V. and as Trustee (June 14th, 2018)
uniQure N.V. – UNIQURE N.V. and as Trustee (June 14th, 2018)
uniQure N.V. – UNIQURE N.V. EMPLOYEE STOCK PURCHASE PLAN (June 14th, 2018)

The following constitute the provisions of the uniQure N.V. Employee Stock Purchase Plan, effective as of June 13, 2018, subject to approval by the Company’s shareholders (the “Plan”).

uniQure N.V. – uniQure N.V. 2014 Share Incentive Plan (Amended and Restated effective as of June 13, 2018) (June 14th, 2018)
uniQure N.V. – Rutgers Posch Visée Endedijk N.V. (May 3rd, 2018)
uniQure N.V. – uniQure N.V. 4,500,000 Ordinary Shares (Nominal Value € 0.05 Per Share) UNDERWRITING AGREEMENT (May 3rd, 2018)

uniQure N.V., a Dutch public company with limited liability (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 4,500,000 ordinary shares, nominal value €0.05 per share (the “Ordinary Shares”).  The 4,500,000 Ordinary Shares to be sold by the Company are called the “Firm Shares.”  In addition, the Company has granted to the Underwriters an option to purchase up to an additional 675,000 Ordinary Shares as provided in Section 2.  The additional 675,000 Ordinary Shares to be sold pursuant to such option are called the “Optional Shares.”  The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.”  Leerink Partners LLC (“Leerink”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwr

uniQure N.V. – Annual Report 2017 uniQure N.V. (April 30th, 2018)
uniQure N.V. – Performance Share Unit Agreement (March 14th, 2018)

This Performance Share Grant Unit Agreement (this “Agreement”) is made as of the Grant Date between uniQure N.V., a public limited company incorporated under the laws of the Netherlands (the “Company”) and the Participant.

uniQure N.V. – Restricted Share Unit Agreement (March 14th, 2018)

This Restricted Share Unit Grant Agreement (this “Agreement”) is made as of the Grant Date between uniQure N.V., a public limited company incorporated under the laws of the Netherlands (the “Company”) and the Participant.

uniQure N.V. – ~ On Track to Begin Pivotal Study of AMT-061 in Hemophilia B in Q3 2018 ~ Submitted IND Amendment for AMT-061 Dose Confirmation Study, with Topline Data Expected by End of 2018 (March 14th, 2018)

Lexington, MA and Amsterdam, the Netherlands, March 14, 2018 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for 2017 and highlighted recent progress across its business.

uniQure N.V. – uniQure N.V. Share Option Agreement (December 14th, 2017)
uniQure N.V. – uniQure N.V. Restricted Share Unit Agreement NOTICE OF GRANT (December 14th, 2017)

This Restricted Share Unit Grant Agreement (this “Agreement”) is made as of the Grant Date between uniQure N.V., a public limited company incorporated under the laws of the Netherlands (the “Company”) and the Participant.

uniQure N.V. – October 26, 2017 Matthew Kapusta (November 1st, 2017)
uniQure N.V. – uniQure N.V. 5,000,000 Ordinary Shares (Nominal Value € 0.05 Per Share) UNDERWRITING AGREEMENT (October 26th, 2017)

uniQure N.V., a Dutch public company with limited liability (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 5,000,000 ordinary shares, nominal value €0.05 per share (the “Ordinary Shares”).  The 5,000,000 Ordinary Shares to be sold by the Company are called the “Firm Shares.”  In addition, the Company has granted to the Underwriters an option to purchase up to an additional 750,000 Ordinary Shares as provided in Section 2.  The additional 750,000 Ordinary Shares to be sold pursuant to such option are called the “Optional Shares.”  The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.”  Leerink Partners LLC (“Leerink”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwr

uniQure N.V. – Rutgers Posch Visée Endedijk N.V. Herengracht 466, 1017 CA Amsterdam P.O. Box 10896, 1001 EW Amsterdam The Netherlands T + 31(0)20 891 3900 | F + 31(0)20 891 3901 www.rutgersposch.com (October 26th, 2017)
uniQure N.V. – ~ Issued Patent in the U.S. Covers Use of FIX-Padua in Gene Therapy ~ ~ Divisional patent applications filed to further strengthen Padua intellectual property position ~ (October 19th, 2017)

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 19, 2017 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company has acquired a patent family, with claims issued in the U.S., that broadly covers a hyperactive variant of Factor IX carrying an R338L mutation (often referred to as “FIX-Padua”) and its use in gene therapy for the treatment of coagulopathies, including hemophilia B. This patent family was acquired from the inventor, Professor Paolo Simioni, a renowned hemophilia expert at the University of Padua, Italy, who is widely recognized as the first to identify this mutant.

uniQure N.V. – ASSIGNMENT AND LICENSE AGREEMENT (October 19th, 2017)

THIS ASSIGNMENT AND LICENSE AGREEMENT (this “Agreement”) is dated as of April 17, 2017 (the “Effective Date”), by and between Professor Paolo Simioni, with a place of business at via Barbo 8, Padova 35128, Italy (“Simioni”), and uniQure biopharma B.V., with a place of business at Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands (“uniQure” and collectively with Simioni, the “Parties” and each, a “Party”).

uniQure N.V. – Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. Confidential treatment has been requested with respect to the omitted portions. Double asterisks denote omissions. (September 29th, 2017)
uniQure N.V. – Rutgers Posch Visée Endedijk N.V. (September 18th, 2017)
uniQure N.V. – uniQure N.V. Up to 5,000,000 Ordinary Shares (nominal value €0.05 per share) SALES AGREEMENT (September 18th, 2017)

uniQure N.V., a Dutch public company with limited liability (naamloze vennootschap) (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (“Leerink”), as follows:

uniQure N.V. – EMPLOYMENT AGREEMENT (August 8th, 2017)

THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of July 10, 2017 (the “Effective Date”), by and between uniQure, Inc., 113 Hartwell Avenue, Lexington, MA 02421 (the “Company”) and Scott T. McMillan (the “Executive”),  109 Hayward Road, Acton, MA 01720.

uniQure N.V. – employment AGREEMENT PURSUANT TO SECTION 7:610 (et seq.) of the Dutch Civil Code (DCC) August 4, 2017 (August 8th, 2017)
uniQure N.V. – uniQure biopharma B.V. Paasheuvelweg 25a 1105BP Amsterdam The Netherlands (August 8th, 2017)
uniQure N.V. – employment AGREEMENT PURSUANT TO SECTION 7:610 (et seq.) of the Dutch Civil Code (DCC) [July 15, 2017] (August 8th, 2017)
uniQure N.V. – UNIQURE N.V. (May 15th, 2017)
uniQure N.V. – UNIQURE N.V. and as Trustee INDENTURE Dated as of , 20 Senior Debt Securities (May 15th, 2017)
uniQure N.V. – UNIQURE N.V. and as Trustee (May 15th, 2017)
uniQure N.V. – CO-DEVELOPMENT AND LICENSE AGREEMENT (May 9th, 2017)

This Co-Development and License Agreement (this “Agreement”) is entered into as of 29 April 2013 (the “Effective Date”), by and between uniQure Biopharma B.V., formerly known as Amsterdam Molecular Therapeutics (AMT) B.V., a Dutch corporation, with its offices at Meibergdreef 61, 1105 BA Amsterdam, The Netherlands (“uniQure”), and Chiesi Farmaceutici S.p.A., an Italian corporation, with its offices at Via Palermo, 26/A, 43122 Parma, Italy (“Chiesi”). uniQure and Chiesi are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.